Mario Tiribelli

65PUBLICATIONS
141CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersMedical mycologyImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Oct 08, 2026
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.

|Jul 22, 2026
Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

|Jun 11, 2026
A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

|Mar 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Paola Guglielmelli, Massimo Breccia, Francesco Mendicino

|Feb 21, 2026
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Francesca Palandri, Venediktos Kapetanakis, Balázs Dobi

Pageof 11

Frequent Collaborators

35 joint publications

Massimo Breccia

28 joint publications

Massimiliano Bonifacio

27 joint publications

Elisabetta Abruzzese

21 joint publications

Francesca Palandri